- This topic has 1 reply, 1 voice, and was last updated 2 weeks, 5 days ago by
.
-
Posts
-
-
-
• Medical crowdfunding platforms (ImpactGuru and similar) are the most commonly used route specifically for Zolgensma and Spinraza costs, given the crore-level amounts involved; they are less necessary for generic Risdiplam given its much lower annual cost.
• Novartis has offered instalment/payment-plan structures for Zolgensma in at least one documented case in India, with an initial instalment reported around Rs 9 crore against a total of roughly Rs 9 crore-plus — ask your treating centre directly whether a manufacturer patient-access program applies to your case, since terms are not standardized or publicly advertised.
• Check both government and private health insurance policies for genetic/rare-disease riders. Coverage is inconsistent across insurers and is worth verifying case by case — do not assume exclusion or inclusion without asking in writing.
• The National Policy for Rare Diseases (NPRD) 2021 provides financial assistance, in some categories up to Rs 50 lakh, for treatment at designated Centres of Excellence (CoEs). Implementation, disease-specific coverage, and whether SMA-specific therapies (Risdiplam, Zolgensma) are included vary by state and by CoE — confirm directly with your nearest CoE rather than assuming SMA is automatically covered.
• CureSMA India (Topic 7) and ORD India both maintain advocacy channels specifically pushing for broader drug accessibility and can point families toward currently active assistance programs, since these change faster than any static forum post can track.
-
- You must be logged in to reply to this topic.